Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) secured EU marketing authorization for its PD-1 inhibitor, Serplulimab, in combination with carboplatin and etoposide for treating extensive-stage small cell lung cancer.
The approval grants the drug centralized marketing rights across all EU member states, Iceland, Liechtenstein and Norway, according to a Wednesday filing with the Shanghai bourse.
Shares of the pharnaceutical company rose 1% in recent trade on the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.